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ClusterinAbstract Chronic kidney disease (CKD) is a progressive pathological condition marked by dete-
riorating renal function over time. Diagnostic of kidney disease depend on serum creatinine level
and glomerular ﬁltration rate which is detectable when kidney function become half. The detection
of kidney damage in an early stage needs robust biomarkers. Biomarkers allow monitoring the dis-
ease progression at initial stages of disease. On the onset of impairment in cellular organization
there is perturbation in signaling molecules which are either up-regulated or down-regulated and
act as an indicator or biomarker of diseased stage. This review compiled the cell signaling of differ-
ent kidney biomarkers associated with the onset of chronic kidney diseases. Delay in diagnosis of
CKD will cause deterioration of nephron function which leads to End stage renal disease and at
that point patients require dialysis or kidney transplant. Detailed information on the complex
network in signaling pathway leading to a coordinated pattern of gene expression and regulation
in CKD will undoubtedly provide important clues to develop novel prognostic and therapeutic
strategies for CKD.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.Contents
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Cells use a large number of clearly deﬁned signaling pathways
to regulate their activity. (Mendoza et al., 2011; Schneider
et al., 2012). Phenotypic modiﬁcation and chaotic of signaling
pathways lead to critical diseases in human like mental illness,
hypertension, heart disease, diabetes, kidney disease etc. On
the onset of impairment in cellular organization there is pertur-
bation in signaling molecules which are either up-regulated or
down-regulated and act as an indicator or biomarkers of dis-
eased stage (Rifai et al., 2006).
Chronic kidney disease (CKD) is characterized by progres-
sive destruction of the renal parenchyma and the loss of func-
tional nephrons, which ﬁnally lead to chronic renal failure
(Amandine et al., 2010). CKD progresses slowly and their
mechanism is not well understood. CKD leads to the reduction
of functional nephrons and for the compensation nephrons
triggers molecular and cellular events promoting compensa-
tory growth of the remaining ones (Hostetter, 1995). In some
cases, this compensatory process becomes pathological, with
the development of renal lesions and End stage renal disease
(Kliem et al., 1996; Pillebout et al., 2003; Terzi et al., 1995).
In CKD clinical diagnosis is dependent on levels of blood urea,
nitrogen and serum creatinine. Serum creatinine, however, has
shortcomings because of its low predictive value. Therefore,
next generation that is candidate biomarkers are being identi-
ﬁed for early diagnosis of CKD (Charles, 2008). Biomarkers
are protein and act as signaling molecule in diseased state. In
this review, attention is focused on intracellular signaling path-
way of biomarkers associated with the onset of kidney impair-
ment. During the process of development of disease, speciﬁc
protein selects their signaling systems that are suitable to con-
trol their particular functions. This review is all about cell-spe-
ciﬁc biomarker function to regulate different signaling
pathways in response to chronic kidney damage.Table 1 Characteristics of biomarkers.
Biomarkers Discovery Nat
Asymmetric
dimethylarginine
Vallance et al., 1992 ﬁrst reported
the role of asymmetric dimethylarginine
It is
chem
Clusterin Fritz et al., 1983 was ﬁrst identiﬁed
in ram rete testis ﬂuid.
75–
hete
Neutrophil
gelatinase-associated
lipocalin
Kjeldsen et al., 2000 ﬁrst identiﬁed
this protein as a component
of neutrophil granules
25 k
in n
Hepatocyte
growth factor
Nakamura et al., 1984 ﬁrst identiﬁed
and puriﬁed Hepatocyte growth
factor in rat
It is
poly
69-k
34-kThis review updates the reader on the current status of
biomarker signaling associated with kidney impairment. At
present, the main contenders include Asymmetric dimethylar-
ginine, clusterin, Neutrophil gelatinase-associated lipocalin,
and Hepatocyte growth factor. Characteristics of these
biomarkers are presented in Table 1.
1.1. Signaling pathways associated with Asymmetric
dimethylarginine and CKD
Asymmetric dimethylarginine (ADMA), an analog of L-argi-
nine, is a naturally occurring product of metabolism found
in human circulation. Elevated levels of ADMA inhibit nitric
oxide (NO) synthesis and therefore impair endothelial function
and thus promote kidney impairment (Vallance et al., 1992).
Nitric oxide is a major player in the regulation of renal func-
tion. Increased levels of ADMA have been shown to be the
strongest risk predictor (Hasdan et al., 2002; Kielstein et al.,
2002; Passauer et al., 2005; Zoccali et al., 2001) and are
involved in the evolution of progressive nephropathies sug-
gested by two studies. Both studies concluded high ADMA
constantly predicted a faster rate of renal function loss and
lend support to the hypothesis that ADMA may engender
renal damage as it triggers glomerular hypertension, endothe-
lial damage, salt accumulation, and cell senescence (Fliser
et al., 2005; Ravani et al., 2005).
Matsuguma et al. (2006) explored the molecular mechanism
for increase in ADMA and its role for hypertension in CKD
using a rat remnant kidney model. Production of ADMA in
cell is through an enzyme protein methyltransferase (PRMT)
(Boger et al., 2000) and metabolized mainly by NG, NG-
dimethylarginine dimethylaminohydrolase (DDAH) (Leiper
and Vallance, 1999; Ogawa et al., 1998; Ueda et al., 2003).
Results of semiquantitative reverse transcription-PCR and
Western blot showed that DDAH protein levels as well asure Signaling pathways
a metabolic by-product
ical found in blood plasma
It involves in transforming growth
factor-beta, nuclear factor-jB and
Mitogen-activated protein kinase
signaling pathways
80 kDa disulﬁde-linked
rodimeric protein
It involves in transforming growth
factor-beta, signaling pathway
Da protein and expressed
eutrophils
It involves in Epidermal growth
factor receptor and Mitogen-
activated protein kinase signaling
pathways
secreted as a single inactive
peptide and consists of
Da alpha-chain and
Da beta-chain
It involves in phosphatidylinositol
3-kinase-Akt, growth factor-beta,
nuclear factor-jB and the Stat3
signaling pathways
296 Z. Khan, M. Pandeyincreased PRMT gene expression may cause the elevation of
plasma ADMA levels in kidney by inhibiting the production
of endothelial nitric oxide, thereby bring out hypertension in
CKD. The mechanism is represented in Fig. 1.
Another signaling involved in ADMA associated kidney
injury is through transforming growth factor (TGF-b) and
nuclear factor-jB (NF-jB) pathways. Wang and co-worker
(2012) explored the mechanism by treating the human renal
glomerular endothelial cells (HRGECs) with long term low
dose of ADMA. Exogenous ADMA notably increased stress
ﬁber formation in HRGECs and upregulated nuclear factor-
jB (NF-jB) and TGF-b expression. Further to inhibit the
stress ﬁber formation, HRGECs were treated with actin depo-
lymerizing and stabilizing agent, p38 MAPK inhibitor and
NADPH oxidase to elucidate that actin cytoskeleton may be
involved in the modulation of ADMA-induced nuclear fac-
tor-jBNF-jB activation and the following TGF-b expression
in human renal glomerular endothelial cells. The same research
was reported by Feng et al., 2013 in endothelial cells.
Kajimoto et al. (2012) had explored the novel mechanism of
ADMA signaling link with impaired endothelial function in
CKD. Fig. 1 explains the ADMA signaling. Study divulged
that ADMA reduces arterial endothelial nitric oxide synthase
(eNOS) phosphorylation by inhibiting Ca/Calmodulin-Depen-
dent Protein Kinase CaMKII (one of the upstream kinases for
eNOS activation)-mediated signaling showing that ADMA
may also reduce nitric oxide production via decreased eNOS
phosphorylation; this effect is mediated by the mitogen-acti-
vated protein kinases (MAPK) pathway and can be reversed
in vivo by increased catabolism of ADMA through dimethylar-
ginine dimethylaminohydrolase-1 over expression.1.2. Signaling pathways associated with clusterin and CKD
Clusterin also termed as complement cytolysis inhibitor, tes-
tosterone repressed prostate message-2 (TRPM-2), dimenic
acidic glycoprotein (DAG), SP-40, gp8O, apobipoprotein J
and NA 1/N A 2. It is disulﬁde-linked heterodimeric glycopro-
tein of 75 kD, consisting of a- and b-subunits (Jones andFigure 1 Plasma ADMA level is controlled by DDAH. In CKD,
ADMA level is elevated which stops the production of CAMKII
(via MAPK pathway), eNOS and NO. Elevated levels of ADMA
inhibit Nitric oxide (NO) synthesis and therefore impair endothe-
lial function and thus promote kidney impairment. MAPK
(Mitogen activated protein kinase); DDAH (NG, NG-dimethyl-
arginine dimethylaminohydrolase); PRMT (protein methyltrans-
ferase); eNOS (endothelial nitric oxide synthase).Jomary, 2002; Kujiraoka et al., 2004). Clusterin is coupled
with different biologic functions comprised of reproduction,
cell regression, cell aggregation, and regulation of the cytolytic
activity of the membrane attack complex of complement
(Caccamo et al., 2004; Redondo et al., 2002). Up-regulation
of clusterin suggests the occurrence of renal injury and proves
to be a potential biomarker of nephrotoxicity (Girton et al.,
2002). Clusterin is a component of glomerular immune depos-
its in the kidney and clusterin protein is translated in the renal
tubular epithelium after de novo expression of clusterin mRNA
following renal injury, and by post translation processing it is
immediately converted into 2 subtypes. The a subtype was
excreted in the urine and the b subtype was accumulated in
the cytoplasm of the renal tubular epithelial cells (Saunders
et al., 1994).
Different pathways were reported to be associated with
clusterin in response to kidney damage. Studies reported that
expression of clusterin is associated with the signaling pathway
of TGF b. unilateral ureteral obstruction (UUO) kidney is the
condition of marked interstitial ﬁbrosis. Clusterin is over
expressed in UUO kidney and conﬁrmed by the up-regulation
of ﬁbronectin.
Liu, 2006 reported that TGF b 1 plays an important role in
the process of ﬁbrosis. Expression of clusterin is induced by
TGF b 1 via the activation of AP-1 transcriptor protein and
protein kinase C (Jin and Howe, 1997). Diagrammatic repre-
sentation is shown in Fig. 2.
Clusterin is expressed on the dedifferentiated tubular
cells after injury in polycystic kidney disease and renal cell
carcinoma (Correa-Rotter et al., 1998; Harding et al., 1991).
Kidney cancer cells express nuclear form and secretory form
of clusterin (sCLU) which are upregulated after molecular
stress and found to be antiapoptotic and prosurvival in nature.
Shannan et al. (2006) revealed the role of clusterin to cure kid-
ney and other cancer which expresses secretory form of cluster-
in. Finding suggests that by using antisense oligonucleotides or
short interfering double-stranded RNA with the help of some
drugs targeting sCLU may become novel strategy for cancer
therapy, especially in the treatment of kidney, prostate, colon,
breast, and lung tumors that over express sCLU.Figure 2 Clusterin is over expressed in kidney ﬁbrosis. AP 1
protein and protein kinase C enzyme in TGF b 1 pathway trigger
the expression of clusterin.
Figure 3 Renal tubular cells treated with epidermal growth
factor activates EGF receptor protein which further activates
HIF-1 a protein and promotes the formation of NGAL mRNA
thus increases the process of CKD.
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gelatinase-associated lipocalin and CKD
Neutrophil gelatinase-associated lipocalin (NGAL) also called
Lnc2 is a member of a family of over 20 proteins called lipoca-
lins which function in intracellular chemical signaling (Xu
et al., 1994). NGAL is one of the ﬁrst molecules to trigger kid-
ney development, expressed by the ureteric bud. It has been
shown to convert embryonic mesenchymal cells into epithelial
cells which form tubules and then complete nephrons (Yang
et al., 2002a,b). NGAL is present in the kidney proximal
tubule in a patchy distribution and has recently been found
to be expressed in patients with CKD (Bolignano et al.,
2009). The level of NGAL expression appears to be related
to the degree of kidney dysfunction and may even be able to
predict which patients are going to have a faster decline in their
kidney function. Viau et al. (2010) used genomic approach to
delineate a novel mechanism of progression of CKD through
cross talk between NGAL and EGFR. NGAL acts as a growth
regulator by mediating the mitogenic effect of epidermal
growth factor receptor (EGFR) signaling. Activation of the
EGFR stimulates hypoxia-inducible factor (HIF-1a) and ensu-
ing expression of LCN2 resulting in increased cell prolifera-
tion, cytogenesis, renal damage and CKD progression. Fig. 3
presents the signaling of NGAL, EGFR and HIF-1 a in renal
tubular cells leading to CKD.
Mao et al. (2011) explored the signaling of NGAL receptor
named NGALR (NGAL receptor) in injured glomeruli and
investigated the possible mechanism of the NGALR involve-
ment in inﬂammation in human mesangial cells (HMC). The
ﬁndings showed that NGALR is differentially expressed in
human glomerular disease and is signiﬁcantly up-regulated
by interleukin Il-1b in HMC via MAPK/ERK activation.Figure 4 Anti-inﬂammatory and apoptotic activities of HGF.
Bcl-2, c-Met and HGF levels are increased in UUO CKD while
decreased in MCP-1 and RANTES protein level helps in delayed
CKD progression.1.4. Signaling pathway associated with hepatocyte growth factor
and CKD
Hepatocyte growth factor (HGF) is a heterodimer, mesenchy-
mally derived, pleiotropic, and multifunctional cytokine con-
sisting alpha-chain and a beta-chain of 60-kDa and 34-kDa,
respectively (Nakamura et al., 1995). HGF is also known as
a renotrophic factor, and highly expressed in kidney cells
(Ishibashi et al., 1992; Matsumoto and Nakamura, 2001).
HGF is highly involved in the signaling of CKD. HGF
binds to its tyrosine kinase receptor, c-Met, and activates var-
ious signaling pathways (Furge et al., 2000; Stuart et al., 2000),
including cell growth via phosphatidylinositol 3-kinase-Akt,
cell proliferation via Ras-Mek-Erk, cell inﬂammation via
NF-jB, TGF beta-1 pathway and the Stat3 pathways.
HGF slows down the progression of chronic obstructive
nephropathy reported by Gao et al. (2002). Researchers
worked on apoptotic signaling pathway and found that after
liposome mediated HGF gene transfer in unilateral ureteral
obstruction (UUO) rats, HGF and c-Met were up-regulated
in UUO kidneys and apoptotic pathway molecule Bcl-2 pro-
tein was found to be up regulated while no changes were found
in Bcl-xl and Bax protein. Fig. 4 explains the increased HGF
protein level in unilateral ureteral obstruction kidney with
the activation of apoptotic pathway proteins.
Gong et al. (2006) explained anti-inﬂammatory activity of
HGF in inﬂamed renal interstitial kidney of rat. Researchers
worked on the expression of the chemokines macrophage che-
moattractant protein-1 (MCP-1) and RANTES (regulated
upon expression normal T cell expressed and secreted) which
are down regulated in inﬂamed condition of glomeruli and
tubulointerstitium. In-vitro study revealed that HGF down
regulated TNF-a-induced expression of MCP-1 and RANTES
at both the mRNA and protein levels in proximal tubular epi-
thelial cells. TNF-a stimulates nuclear translocation and acti-
vation of NF-jB, a key transcription factor that regulates
chemokine expression is also halted by HGF. Diagrammatic
representation of antiinﬂammatory activity of HGF is
explained in Fig. 4.2. Conclusion
Increasing knowledge in the science of biology and medicine
has accelerated the discovery of novel biomarkers and eluci-
dated their roles in molecular pathways triggered by physiolog-
ical and/or pathological conditions. The detection of kidney
disease genes holds great promise for detecting novel pathways
that initiate renal ﬁbrosis and lead to progressive loss of renal
function. Detailed information on the complex network in sig-
naling pathway leading to a coordinated pattern of gene
expression and regulation in CKD will undoubtedly provide
important clues to develop novel prognostic and therapeutic
strategies for CKD. Above mentioned pathways allied with
kidney impairment are likely to offer new therapies that may
slow or halt development of chronic kidney failure.Acknowledgements
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